Table 1.
Characteristics of included studies
| Study | Inclusion criteria | Patients (n) | ICD (n) | Follow-up (months) | Main result |
|---|---|---|---|---|---|
| MADIT, 1996 | EF ≤0.35; MI ≥3 weeks before entry; NSVT; NYHA I–III | 196 | 95 | 27 | ICD therapy resulted in 54% RR reduction, P = 0.009 |
| CABG Patch, 1997 | EF ≤0.35; abnormal SAECG, scheduled for CABG; NYHA I–III | 900 | 446 | 32 | ICD therapy did not reduce mortality, P = 0.64 |
| CAT, 2002 | EF ≤0.30; new onset DCM; NYHA II–III | 104 | 50 | 66 | ICD therapy did not reduce mortality, P = 0.55 |
| MADIT II, 2002 | EF ≤0.30; MI ≥1 month before entry; NYHA I–III | 1232 | 742 | 20 | ICD therapy resulted in 31% RR reduction, P = 0.016 |
| AMIOVIRT, 2003 | EF ≤0.35; DCM; asymptomatic NSVT; NYHA I–III | 103 | 51 | 36 | ICD therapy did not reduce mortality, P = 0.80 |
| DEFINITE, 2004 | EF ≤0.35; DCM; NSVT, NYHA I–III | 458 | 229 | 29 | ICD therapy resulted in 35% RR reduction, P = 0.08 |
| DINAMIT, 2004 | EF ≤0.35; within 6–40 days of MI; NYHA I–III; abnormal HRV | 674 | 332 | 33 | ICD therapy did not reduce mortality, P = 0.66 |
| SCD-HeFT, 2005 | EF ≤0.35; 3 months optimal medical therapy; NYHA II–III | 2521 | 829 | 45.5a | ICD therapy resulted in 23% RR reduction, P = 0.007 |
AMIOVIRT, Amiodarone vs. Implantable Defibrillator Randomized Trial; CABG Patch, Coronary Artery Bypass Graft Patch trial; CAT, Cardiomyopathy Trial; DCM, dilated cardiomyopathy; DEFINITE, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Defibrillator in Acute Myocardial Infarction Trial; EF, left ventricular ejection fraction; HRV, heart rate variability; MADIT, Multicenter Automatic Defibrillator Implantation Trial; MI, myocardial infarction; NYHA, New York Heart Association; NSVT, non-sustained ventricular tachycardia; SAECG, signal-averaged ECG; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
aMedian